Zhong Ji Longevity Advances IP Transfer to Clear Key Condition for Stem Cell Unit Acquisition

An update from Zhong Ji Longevity Science Group Limited ( (HK:0767) ) is now available.

Zhong Ji Longevity Science Group Limited has updated investors on conditions tied to its planned acquisition of 25% of Asian Integrated Cell Laboratory Limited, to be settled via the issue of convertible notes. The deal hinges on the transfer of key intellectual property in stem cell technologies, including patents in China and Hong Kong, into the target company.

A supplemental agreement signed on 2 April 2026 confirms that the guarantor has transferred the relevant IP into two intermediary companies and already shifted all shares of the Hong Kong entity to the target company without consideration. The remaining step is the no-cost transfer of the PRC company’s shares to the target, after which the IP transfer condition will be deemed fulfilled and the sale and purchase terms adjusted, helping clear a major hurdle for completion of the connected transaction.

The most recent analyst rating on (HK:0767) stock is a Sell with a HK$0.47 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

More about Zhong Ji Longevity Science Group Limited

Zhong Ji Longevity Science Group Limited, incorporated in Bermuda and listed in Hong Kong under stock code 767, operates in the longevity and medical science sector. Through related entities such as Zhong Ji 1 Longevity Medical Group and PRC-based investment arms, it focuses on stem cell and regenerative medicine technologies, particularly involving umbilical cord-derived mesenchymal stem cells.

Average Trading Volume: 379,539

Technical Sentiment Signal: Sell

Current Market Cap: HK$312M

See more insights into 0767 stock on TipRanks’ Stock Analysis page.